Extracorporeal schok wave therapy on breast cancer-related lymphdema

Not Applicable

Recruiting

• Conditions: Breast-cancer related lymphedema; C15.604.496

• Registration Number: RBR-427kc5t
• Lead Sponsor: Centro Universitário das Faculdades Associadas de Ensino - FAE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-22
• Last Update Posted: 29 May 2023
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Participants with secondary upper limb lymphedema after breast cancer (identified by the truncated cone formula, considered lymphedema when the difference in limb volume is greater than 200 ml); Age between 18 and 65 years; (Higher incidence of breast cancer in this age group); Female gender (higher population affected by this type of neoplasm)

Exclusion Criteria

Decompensated heart disease or metabolic disorders; Skin lesions such as dermatitis and dermatosis; History of deep vein thrombosis; Smokers; Participants who had electronic implants, such as cardiac pacemakers.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in limb volume with and without lymphedema measured by the truncated cone formula, considering lymphedema when the difference in limb volume is greater than 200 ml. The primary outcome is expected to be a reduction of at least 10% of the initial volume presented.;Difference between the limb with lymphedema and without the presence of lymphedema as measured by the thickness of the subcutaneous tissue using ultrasonography. The Healcerion Sonon 300L ultrasound will be used. Through it it will be possible to measure the thickness of the subcutaneous tissue in two points: 10 cm above the olecranon, following a straight line along the humerus; and the other point 10 cm below the humeral head in a straight line along the humerus. A minimum 10% reduction in the thickness of the subcutaneous tissue presented is expected as a secondary endpoint.